ValuEngine lowered shares of United Therapeutics Corporation (NASDAQ:UTHR) from a buy rating to a hold rating in a report published on Friday morning.

Other research analysts also recently issued reports about the company. BidaskClub downgraded United Therapeutics Corporation from a buy rating to a hold rating in a research note on Wednesday, July 19th. Zacks Investment Research downgraded United Therapeutics Corporation from a hold rating to a sell rating in a research note on Thursday, July 13th. Jefferies Group LLC restated a sell rating and set a $105.00 price objective on shares of United Therapeutics Corporation in a research note on Friday, July 14th. Finally, UBS AG restated a sell rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. Six analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company. The company presently has an average rating of Hold and an average target price of $134.50.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at 120.75 on Friday. The company’s 50 day moving average price is $130.11 and its 200 day moving average price is $130.35. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89. The firm has a market capitalization of $5.25 billion, a P/E ratio of 14.00 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Zacks’ consensus estimate of $3.61 by $4.86. The company had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. United Therapeutics Corporation’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.42 earnings per share. On average, analysts expect that United Therapeutics Corporation will post $10.09 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “United Therapeutics Corporation (UTHR) Downgraded by ValuEngine to Hold” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/12/united-therapeutics-corporation-uthr-downgraded-by-valuengine-to-hold.html.

In other news, Director Christopher Causey sold 580 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $134.48, for a total transaction of $77,998.40. Following the completion of the sale, the director now directly owns 3,295 shares of the company’s stock, valued at $443,111.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,232 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $133.32, for a total value of $164,250.24. Following the sale, the chief executive officer now directly owns 2,301 shares of the company’s stock, valued at $306,769.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 25,178 shares of company stock valued at $3,289,427. Insiders own 7.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. HPM Partners LLC lifted its holdings in shares of United Therapeutics Corporation by 0.8% during the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 15 shares during the last quarter. First Allied Advisory Services Inc. lifted its holdings in shares of United Therapeutics Corporation by 0.4% during the second quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 19 shares during the last quarter. Nomura Asset Management Co. Ltd. lifted its holdings in shares of United Therapeutics Corporation by 0.3% during the first quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock valued at $1,712,000 after purchasing an additional 40 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in shares of United Therapeutics Corporation by 1.4% during the second quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 45 shares during the last quarter. Finally, Argent Capital Management LLC lifted its holdings in shares of United Therapeutics Corporation by 2.4% during the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock valued at $343,000 after purchasing an additional 60 shares during the last quarter.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.